Recent GWAS investigating the rate of progression of a tauopathy in progressive supranuclear palsy identified variants in a putative enhancer for LRRK2 that increase the rate of progression, implicating LRRK2 in mediating tauopathy pathogenesis (Jabbari et al, 2021). This evidence concerns the gene LRRK2 and Classical progressive supranuclear palsy.